AEON Biopharma, Inc.
We are a clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. We plan to develop ABP-450 to address the estimated $2.2 billion global therapeutic botulinum toxin market, which is projected to grow to $4.4 billion in 2027. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by FDA, Health Canada and EMA. We have exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. We have built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization.
Botulinum toxins have proven to be a highly versatile therapeutic biologic, with over 230 therapeutic uses documented in published scientific literature and 10 approved therapeutic indications in the United States.
(Note: AEON Biopharma postponed its IPO, which was scheduled for pricing on Oct. 7, 2021, to trade on Friday, Oct. 8, 2021, “due to market conditions.”)
|Address||4040 MacArthur Blvd., Suite 260, Newport Beach, CA 92660, US|
|Phone Number||(949) 354-6499|
|View Prospectus:||AEON Biopharma, Inc.|
|Revenues||$1.1 mil (last 12 months)|
|Net Income||$-53.4 mil (last 12 months)|
|Price range||$14.00 - $16.00|
|Est. $ Volume||$75.0 mil|
|Manager / Joint Managers||Wells Fargo Securities/ Cantor|
|CO-Managers||Mizuho Securities/ H.C. Wainwright & Co.|
|Expected To Trade:||10/8/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|